JP7850884B2 - 新規多重特異性抗体 - Google Patents

新規多重特異性抗体

Info

Publication number
JP7850884B2
JP7850884B2 JP2023560715A JP2023560715A JP7850884B2 JP 7850884 B2 JP7850884 B2 JP 7850884B2 JP 2023560715 A JP2023560715 A JP 2023560715A JP 2023560715 A JP2023560715 A JP 2023560715A JP 7850884 B2 JP7850884 B2 JP 7850884B2
Authority
JP
Japan
Prior art keywords
heavy chain
seq
amino acid
acid sequence
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023560715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511871A (ja
Inventor
サイモン・エドワード・プライト
コルネリス・アドリアーン・デ・クライフ
Original Assignee
メルス・ベー・フェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルス・ベー・フェー filed Critical メルス・ベー・フェー
Publication of JP2024511871A publication Critical patent/JP2024511871A/ja
Priority to JP2025179886A priority Critical patent/JP2026026084A/ja
Application granted granted Critical
Publication of JP7850884B2 publication Critical patent/JP7850884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023560715A 2021-03-31 2022-03-30 新規多重特異性抗体 Active JP7850884B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025179886A JP2026026084A (ja) 2021-03-31 2025-10-24 新規多重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2027891 2021-03-31
NL2027891 2021-03-31
PCT/NL2022/050174 WO2022211625A1 (en) 2021-03-31 2022-03-30 Novel multispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025179886A Division JP2026026084A (ja) 2021-03-31 2025-10-24 新規多重特異性抗体

Publications (2)

Publication Number Publication Date
JP2024511871A JP2024511871A (ja) 2024-03-15
JP7850884B2 true JP7850884B2 (ja) 2026-04-24

Family

ID=76035095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023560715A Active JP7850884B2 (ja) 2021-03-31 2022-03-30 新規多重特異性抗体
JP2025179886A Pending JP2026026084A (ja) 2021-03-31 2025-10-24 新規多重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025179886A Pending JP2026026084A (ja) 2021-03-31 2025-10-24 新規多重特異性抗体

Country Status (13)

Country Link
US (1) US20240309115A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314061A1 (cg-RX-API-DMAC7.html)
JP (2) JP7850884B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230165256A (cg-RX-API-DMAC7.html)
CN (2) CN118165116A (cg-RX-API-DMAC7.html)
AU (1) AU2022251985A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020141A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213796A1 (cg-RX-API-DMAC7.html)
IL (1) IL307332A (cg-RX-API-DMAC7.html)
MX (1) MX2023011362A (cg-RX-API-DMAC7.html)
PH (1) PH12023552704A1 (cg-RX-API-DMAC7.html)
TW (1) TW202302630A (cg-RX-API-DMAC7.html)
WO (1) WO2022211625A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105926QA (en) * 2018-12-31 2021-07-29 Merus Nv Truncated multivalent multimers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019009728A1 (en) 2017-07-06 2019-01-10 Merus N.V. ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
WO2020038397A1 (en) 2018-08-21 2020-02-27 I-Mab Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
WO2020229626A1 (en) 2019-05-14 2020-11-19 F-Star Delta Limited Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
WO2020249071A1 (en) 2019-06-12 2020-12-17 Nanjing GenScript Biotech Co., Ltd. Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3515951B1 (en) 2016-09-23 2024-02-28 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
TWI917306B (zh) 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019009728A1 (en) 2017-07-06 2019-01-10 Merus N.V. ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
WO2020038397A1 (en) 2018-08-21 2020-02-27 I-Mab Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
WO2020229626A1 (en) 2019-05-14 2020-11-19 F-Star Delta Limited Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
WO2020249071A1 (en) 2019-06-12 2020-12-17 Nanjing GenScript Biotech Co., Ltd. Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof

Also Published As

Publication number Publication date
CN118165116A (zh) 2024-06-11
JP2026026084A (ja) 2026-02-16
CA3213796A1 (en) 2022-10-06
AU2022251985A1 (en) 2023-10-19
PH12023552704A1 (en) 2024-02-19
JP2024511871A (ja) 2024-03-15
BR112023020141A2 (pt) 2023-11-28
MX2023011362A (es) 2023-10-05
KR20230165256A (ko) 2023-12-05
IL307332A (en) 2023-11-01
CN117157323A (zh) 2023-12-01
EP4314061A1 (en) 2024-02-07
US20240309115A1 (en) 2024-09-19
TW202302630A (zh) 2023-01-16
WO2022211625A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
US11161904B2 (en) Anti-PD-1 antibody and use thereof
US11472882B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
TWI866043B (zh) 細胞毒性t淋巴球相關蛋白4(ctla-4)之新穎單株抗體
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
JP6755866B2 (ja) Cd73特異的結合分子及びその使用
JP2022116257A (ja) 癌の治療に用いるための細胞傷害誘導治療剤
JP7401166B2 (ja) 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用
JP2022526764A (ja) EGFRxCD28多特異性抗体
US20240343803A1 (en) Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
WO2020098734A1 (zh) 抗tigit抗体及其用途
US20250136687A1 (en) Anti-human cd3 antibody and use thereof
JP7843824B2 (ja) 抗体および使用方法
US20250145705A1 (en) Gprc5d antibody and application thereof
KR20230051163A (ko) Tigit 및 cd112r 차단
JP2026026084A (ja) 新規多重特異性抗体
US20250297021A1 (en) Bcma antibody and use thereof
WO2023046113A1 (zh) 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
US20240425595A1 (en) Novel pd-1 binding domains
US20220363761A1 (en) Multispecific binding moieties comprising novel pd-1 binding domains
JP2026508096A (ja) 治療抗体
KR20250135354A (ko) Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
JP2024544386A (ja) Pd-l1抗原結合タンパク質及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260113

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20260212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7850884

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150